News
It’s always amusing to see how minimum-security prisons get characterized in the media. The days of “country club’’ prisons are long gone, and people...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Victor Dergunov is an independent investor and author with 20 years experience. He preaches diversification and shares investment...
News
This article was written by Follow I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on...
News
This article was written by Follow Author and entrepreneur. My articles typically cover macroeconomic trends, portfolio strategy, value investing, and behavioral finance. I like...
News
Following the heavy selling we saw in equities during the summer of 2023, dividend stocks that have larger-than-normal yields were everywhere. The combination of...
News
A Quick Take On Vinci Partners Investments Vinci Partners Investments (NASDAQ:VINP) reported its Q3 2023 financial results on November 8, 2023, reporting year-over-year fee-related...
News
The recently announced capacity restrictions in the Panama Canal have done more than any other factor to reduce effective fleet supply worldwide Investment thesis...
News
Listen above or on the go via Apple Podcasts and Spotify Why Michael Gayed sees Phase 2 of a coming credit event going from...
News
The fascination of shooting as a sport depends almost wholly on whether you are at the right or wrong end of the gun.”― P.G....
News
Stocks continued to rally this week, with the S&P 500 climbing by 1%, approaching their July peak. The rally has been a 3-part move...
News
This article was written by Lawrence Fuller has been managing portfolios for individual investors for 30 years, starting his career at Merrill Lynch in...
News
Retail endured a tough Q3. NIKE (NYSE:NKE) and Target (TGT) were two of the worst large-cap performers, but both names caught a bid as...
News
Deals and Financings Beijing’s BeiGene (BGNE; HK: 06160; SHA: 688235) acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s...
